SPY304.32+1.35 0.45%
DIA254.29-0.06 -0.02%
IXIC9,489.87+120.88 1.29%

Pfizer Highlights New Data From Trials Of 18 Approved, Investigational Medicines Will Be Presented At ASCO 20 Virtual Program May 29-31

Pfizer Inc. (NYSE:PFE) today announced that new data from clinical trials of 18 approved and investigational medicines will be presented virtually at the ASCO20 Virtual Scientific Program, from May 29-May 31. The data

Benzinga · 05/12/2020 16:04

Pfizer Inc. (NYSE:PFE) today announced that new data from clinical trials of 18 approved and investigational medicines will be presented virtually at the ASCO20 Virtual Scientific Program, from May 29-May 31. The data that will be presented build on Pfizer’s strong track record in oncology by providing new insights in areas like breast, colorectal and genitourinary cancers, which include bladder, prostate, and kidney cancer. Data from Pfizer’s early stage pipeline, including a novel anti-HER2 antibody-drug conjugate, will also be presented as Pfizer aims to transform the cancer treatment landscape well into the future.

“Our data presentations will highlight the depth and breadth of our cancer portfolio, including our current medicines and new generation of potential therapies,” said Chris Boshoff, M.D., Ph.D., Chief Development Officer, Oncology, Pfizer Global Product Development. “We are particularly excited to share the first presentation of detailed overall survival results from the JAVELIN Bladder 100 trial of BAVENCIO and the final overall survival data from the PROSPER trial of XTANDI. These data will support our rapidly expanding efforts in bladder cancer and add to the growing body of clinical evidence generated with XTANDI in prostate cancer.”

New data will be featured in nine oral presentations, including a Plenary Session presentation of data from the JAVELIN Bladder 100 trial evaluating BAVENCIO® (avelumab) as a first-line maintenance treatment for locally advanced or metastatic urothelial carcinoma (UC). Additional data provide insights on Pfizer’s medicines, including IBRANCE® (palbociclib), BRAFTOVI® (encorafenib), XTANDI® (enzalutamide) and lorlatinib, as well as its cutting-edge, investigational compounds, including a HER2-targeted antibody-drug conjugate in patients with solid tumors. BAVENCIO is being developed and commercialized in collaboration with Merck KGaA, Darmstadt, Germany. As part of a global agreement, Pfizer and Astellas jointly develop and commercialize XTANDI.

To help interested non-scientists better understand the latest research, Pfizer has also developed summaries in non-technical language for results of company-sponsored studies being presented in the ASCO20 Virtual Scientific Program called “abstract plain language summaries (APLS).” Those interested in learning more can visit www.Pfizer.com/apls to access the summaries directly starting May 29.

Key presentations featuring Pfizer medicines in the ASCO20 Virtual Scientific Program include:

Pfizer-Sponsored Studies

Plenary Session Oral Presentation (Abstract LBA1)

Sunday, May 31, 1 pm ET

 

Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase 3 interim analysis.

 

Powles T

Oral Presentation (Abstract 4001)

 

Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: updated survival results from a randomized, three-arm, phase 3 study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC)

 

Kopetz S

Poster Discussion (Abstract 5515)

 

Final overall survival (OS) from PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC)

 

Sternberg CN

Poster Presentation (Abstract 1039)

 

A phase 1 dose escalation study evaluating the safety and tolerability of a novel anti-HER2 antibody-drug conjugate (PF-06804103) in patients with HER2-positive solid tumors

 

Meric-Bernstam F

Poster Presentation (Abstract 5080)

 

Axitinib plus pembrolizumab in patients with advanced renal cell carcinoma: Long term efficacy and safety from a phase 1b study

 

Atkins MB

Investigator Sponsored Studies and Clinical Research Collaborations

Oral Presentation (Abstract 1010)

 

Prognostic impact of ESR1 mutations in ER+ HER2- MBC patients prior treated with first line AI and palbociclib: An exploratory analysis of the PADA-1 trial

 

Bidard FC

Oral Presentation (Abstract 10504)

 

Phase 1 trial of lorlatinib in patients with ALK-driven refractory or relapsed neuroblastoma: A New Approaches to Neuroblastoma Consortium study

 

Goldsmith KC

Oral, poster discussion, and poster sessions, as well as track-based clinical science symposia, will be available on demand for registered participants beginning Friday, May 29 at 8:00 AM ET. A complete list of Pfizer-sponsored abstracts is available at https://www.pfizer.com/news/press-kits/oncology.

Merck KGaA, Darmstadt, Germany, and Pfizer have a global strategic alliance to jointly develop and commercialize BAVENCIO.

As part of a global agreement, Pfizer and Astellas jointly develop and commercialize XTANDI. The companies jointly commercialize XTANDI in the United States and Astellas has responsibility for manufacturing and all additional regulatory filings globally, as well as commercializing XTANDI outside the United States.

Prescribing Information for Pfizer Medicines

Please see full US Prescribing Information and Medication Guide for BAVENCIO® (avelumab) available at http://www.Bavencio.com.

Please see full Prescribing Information for BRAFTOVI® (encorafenib) at www.braftovihcp.com.

Please see full Prescribing Information for IBRANCE® (palbociclib) at www.Ibrance.com.

Please see full Prescribing Information for INLYTA® (axitinib) at www.Inlyta.com.

Please see full Prescribing Information for LORBRENA® (lorlatinib) at www.Lorbrena.com.

Please see full Prescribing Information for XTANDI® (enzalutamide) at www.Xtandi.com.